RSS

DARZALEX

Genmab’s licensing partner, Janssen Biotech, has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for the use of daratumumab (DARZALEX) in front line multiple myeloma. more

Technology